Submitted by Anonymous (not verified) on 10 October 2023 - 7:51
Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis, Date of authorisation: 26/09/2017, Revision: 30, Status: Authorised
Source: